Genfit S.A.(GNFT)Earnings, Financials & Key Ratios

All resolutions recommended by the Board of Directors approved (quorum: 32.13 %) Lille (France); Cambridge, ( Massachusetts, United States); Zurich (Switzerland); June 15, 2026 - GENFIT (Euronext: GNFT),, a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 15, 2026. The quorum on first convening amounted to 32.13 % and shareholders approved all of the resolutions, with the exception of resolution n°26 which was rejected in accordance with the recommendations of the Board of Directors.

All resolutions recommended by the Board of Directors approved (quorum: 32. 13 %) Lille (France); Cambridge, (Massachusetts, United States); Zurich (Switzerland); June 15, 2026 - GENFIT (Euronext: GNFT),, a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 15, 2026.

L'ensemble des projets de résolutions recommandés par le Conseil d'Administration a été approuvé (quorum: 32,13 %) Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 15 juin 2026 - GENFIT (Euronext: GNFT), société biopharmaceutique engagée dans l'amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd'hui les résultats de son Assemblée Générale Mixte convoquée le 15 juin 2026.